Stock Ratings / Health Care / FBIO / financials

RNXT (31) OSTX (42) ZYBT (40) GOSS (33) ⌘ Pro Terminal →

Fortress Biotech Inc. (FBIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.92 -4.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.90

Fortress Biotech Inc. (FBIO) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $66.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FBIO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Fortress Biotech Inc. (NASDAQ: FBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.92 (-4.00% 1D, market cap $66.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, FBIO ranks #559 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FBIO compare to RNXT and OSTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBIO carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 66.9%, and ROIC of -35.0%. By comparison, RNXT (RenovoRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M) and OSTX (OS Therapies Incorporated) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M). Among the 5-stock peer group, FBIO leads on earnings multiple (N/A) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FBIO?

▼

Per FBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001429260), Fortress Biotech Inc. generated $63.3M in revenue (+9.7% YoY), $37.0M in net income, and -$65.8M in free cash flow against $185.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.90 (-0.91%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FBIO)Realized 20D OHLCV Swing Band: ±9.3%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY FBIO SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)

20D Institutional Volume Accumulation (±9.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.14-12.6% Next Q

Q2 (-2Q)

Grade D$1.87+3.2% Next Q

Q3 (-1Q)

Grade D$1.93-0.5% Next Q

Current

Grade D-$1.92-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FBIO currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.31) and Max Pain ($2.02) forces dealer call-delta covering toward $4.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How FBIO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $84.5M

FY24

Rev $57.7M

FY25

Rev $63.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$63.3M	66.9%	-80%	$37.0M	-$65.8M	-45%
FY 2024	$57.7M	63.8%	-80%	$21.0M	-$80.2M	-45%
FY 2023	$84.5M	66.9%	-80%	$31.0M	-$128.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FBIO)

✓Walkthrough of FBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.52%▼ DESCENDING CHANNEL

2026-10-30O $2.01H $2.01L $1.89C $1.92VOL 193.4K

RES: $2.60SUP: $1.69SMA50: $2.31SMA200: $2.79

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FBIO Butterfly Map → + Track FBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +9.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FBIO)

Health Care Rank #559 of 1016 ⚔️ RNXT vs FBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FBIO vs. RNXT, OSTX, ZYBT, GOSS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fortress Biotech Inc. (FBIO) ranks #559 by composite RQD confidence (39/100, grade D-) and #715 by equity capitalization ($66.7M). Within this direct 5-issuer industry benchmark cohort, FBIO leads on earnings valuation at N/A trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with FBIO at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FBIO ACTIVE Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	Benchmark Subject
RNXT RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	/rnxt-vs-fbio →
OSTX OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	/ostx-vs-fbio →
ZYBT Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	/zybt-vs-fbio →
GOSS Gossamer Bio Inc.	E	33/100	—	—	-35.0%	-2.90%	$65.4M	/goss-vs-fbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001429260

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fortress Biotech Inc. (FBIO) reported GAAP revenue of $63.3M (+9.7% vs. FY2024 revenue of $57.7M , and -25.1% cumulative change since FY2023) , GAAP net income of $37.0M, operating cash flow of -$65.8M, and free cash flow of -$65.8M (+18.0% YoY). On the balance sheet, FBIO closed FY2025 with $185.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$63.3M	$37.0M	-$65.8M	-$65.8M	$185.5M	—
FY2024 (FY)	2024-12-31	$57.7M	$21.0M	-$80.2M	-$80.2M	$144.2M	—
FY2023 (FY)	2023-12-31	$84.5M	$31.0M	-$128.2M	-$128.2M	—	—

3. FBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does FBIO compare to RNXT and OSTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for FBIO?

Where is FBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

FBIO last traded at $1.92 (-4.00% on volume of 196,843 shares), positioning the stock -16.88% below its 50-day simple moving average ($2.31) and -31.18% below its 200-day simple moving average ($2.79). Across its 52-week range of $1.83 to $4.53, FBIO sits at the 3.3% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($1.74 to $2.10).

FBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Fortress Biotech Inc. (FBIO)?

In FY 2025 (10-K), FBIO converted $63.3M of revenue into a 66.9% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: FBIO RQD Cockpit FBIO 12M Forecast FBIO Earnings & Move FBIO Dividends & DRIP FBIO Insiders & 13F FBIO Whale Options FBIO Profit Sankey FBIO News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

FBIO — Fortress Biotech Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:21Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Fortress Biotech Inc. (FBIO) carries a composite score of 39/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $1.92 (-4.00%). Fundamental cash generation scores 4/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 10/20, insider conviction scores 7/20, macro regime alignment scores 8/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score N/A, Piotroski F-Score 5/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $1.83 – $4.53.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), FBIO is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 66.9%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

FBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fortress Biotech Inc. (FBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FBIO Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 80d ago

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 80d ago

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B finan

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 81d ago

Fortress Biotech Q2 Earnings Call Highlights

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claud

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 98d ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety an

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 216d ago

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium’s

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 182d ago

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders th

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 215d ago

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 130d ago

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Recent commentary ties

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FBIO Bull vs. Bear Conversation Board — What's Your Call at $1.92?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FBIO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.69 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is FBIO (D- • RQD 39/100) a Buy at $1.92?

Welcome to the FBIO (Fortress Biotech Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.61 (-16.1%)

Spot @ $1.92

Pump the brakes on FBIO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on FBIO, but look at what you are paying: current EV/EBITDA multiples with 66.9% gross margins. Unless Fortress Biotech Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.38 (+24.0%)

Spot @ $1.92

FBIO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on FBIO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.92 (52-wk range $1.83 - $4.53), any beat on forward guidance forces shorts and underweight funds to chase.